The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020. (Photo by Himanshu Vyas/ Hindustan Times)
The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020. (Photo by Himanshu Vyas/ Hindustan Times)

Sun Pharma to conduct clinical trial of pancreatitis drug in Covid-19 patients

The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020.
Reuters | By Reuters
PUBLISHED ON MAY 29, 2020 03:48 PM IST

Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.

“Nafamostat (has been) identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany,” the company said in a statement https://reut.rs/2BdSD4o.

The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020.

SHARE THIS ARTICLE ON
Close
SHARE
Story Saved
OPEN APP